05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£25,791,815 |
Nicolas Loebel |
3,538,991 |
£583,934 |
Junaid Bajwa |
1,193,697 |
£196,960 |
Jean Duvall |
1,163,529 |
£191,982 |
Jean Charest |
353,356 |
£58,304 |
Simon Sinclair |
256,327 |
£42,294 |
Carolyn Cross |
118,091,377 |
£19,485,077 |
M&G Plc |
40,588,235 |
£6,697,059 |
Robert Cross |
25,858,400 |
£4,266,636 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,492,470 |
CRUX Asset Management |
9,298,090 |
£1,534,185 |
Chelverton Asset Management |
7,957,311 |
£1,312,956 |
11:35 |
324 @ 16.00p |
11:29 |
1,127 @ 16.69p |
09:28 |
12,650 @ 16.18p |
08:48 |
5,000 @ 16.71p |
08:30 |
294 @ 17.00p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research